Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Jaguar Health (JAGX), 154% surge in interest
• Y-mAbs Therapeutics (YMAB), 144% surge in interest
• Adial Pharmaceuticals (ADIL), 125% surge in interest
• Aldeyra Therapeutics (ALDX), 60% surge in interest
• Precision Biosciences (DTIL), 38% surge in interest

Pipeline and key clinical candidates for these companies:

Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Their crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.

Y-mAbs is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The company’s product pipeline includes one FDA-approved product, Danyelza, which targets tumors that express GD2, and one product candidate at the registration-stage, Omblastys, which targets tumors that express B7-H3.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder, or AUD, in heavy drinking patients and was recently investigated in the company’s ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the company’s proprietary companion diagnostic genetic test. The company is also developing adenosine analogs for the treatment of pain and other disorders.

Aldeyra is a clinical-stage biotechnology company whose pre-commercial product candidates are reproxalap, a potential treatment for dry eye disease and allergic conjunctivitis, and ADX-2191, a potential treatment for primary vitreoretinal lymphoma, proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases. In addition, Aldeyra is developing other product candidates, including ADX-629 and chemically related molecules, for the potential treatment of systemic and retinal immune-mediated diseases.

Precision BioSciences is an advanced gene editing company dedicated to improving life with its novel and proprietary ARCUS genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.

Recent news on these stocks:

March 1

A Precision BioSciences 2.5M share Spot Secondary offering priced at $16.00. Guggenheim acted as sole book running manager for the offering.

February 29

Y-mAbs Therapeutics reported Q4 EPS (2c) against a consensus of (20c), and reported Q4 revenue of $23.36M against a consensus of $20.95M. Y-mAbs Therapeutics additionally said it sees FY24 revenue of $95M-$100M, against a consensus of $96.27M. “Y-mAbs has made significant progress across both the development and commercial fronts of our business resulting in a momentous 2023,” said Mike Rossi, CEO. “From a development standpoint, we demonstrated proof-of-concept of our Self-Assembly DisAssembly Pretargeted Radioimmunotherapy platform, showing that GD2-SADA targets and binds to tumors in humans in a Phase 1 trial. We continue to expect to present mature data from Part A of our Phase 1 GD2-SADA clinical trial at a medical meeting in the second half of this year. In addition, we look forward to initiating our CD38-SADA Phase 1 trial this year. While we continue to advance our SADA PRIT platform and programs through clinical development, we are supported by the solid commercial performance of DANYELZA (naxitamab-gqgk). We achieved record quarterly and annual net product revenues, and sales continue trending upward as more high-volume centers deploy DANYELZA for their patients. Our strong financial foundation and operational performance continue to fuel our mission of providing better and safe therapies for a variety of cancers and improve the lives of patients and their families.”

February 28

Adial Pharmaceuticals announced patent number 11,905,562 was issued on February 20 by the United States Patent and Trademark Office. The patent covers the company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.

February 23

Jaguar Health provided an update regarding the status of its listing with The Nasdaq Stock Market. “Jaguar requested a hearing to appeal a potential delisting of the company’s securities from Nasdaq, and I’m pleased to report that a hearing has been scheduled, ” said Lisa Conte, Jaguar’s president and CEO. “The company’s common stock will continue to trade on Nasdaq under the symbol ‘JAGX’ pending the ultimate decision of any appeal process, and Jaguar’s board remains committed to taking all required steps to remain in compliance with Nasdaq’s listing standards.” As previously reported, on May 10, 2023 Jaguar was notified by Nasdaq’s Listing Qualifications Staff that the bid price for the company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing on Nasdaq. The company was granted a grace period until May 6, 2024, to regain compliance. On February 15, 2024, the company received a letter from the Staff indicating that as of February 14, 2024, the company’s common stock had a closing bid price of $0.10 or less for 10 consecutive trading days, subjecting the company to the provisions of Nasdaq’s “Low Priced Stocks Rule,” and indicating Nasdaq’s intention to delist the company’s securities from Nasdaq on February 26, 2024, unless the company requests an appeal before the Nasdaq Hearings Panel.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.